| Sarah Belcher, SLP | |
|
494 W Central Ave, Delaware, OH 43015-1470 | |
| (740) 369-3650 | |
| Not Available |
| Full Name | Sarah Belcher |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 494 W Central Ave, Delaware, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154524189 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SP8508 (Ohio) | Secondary |
| 235Z00000X | Speech-language Pathologist | SP.08508 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sarah Belcher, SLP 494 W Central Ave, Delaware, OH 43015-1470 Ph: (740) 369-3650 | Sarah Belcher, SLP 494 W Central Ave, Delaware, OH 43015-1470 Ph: (740) 369-3650 |
News Archive
Many women at high risk for breast cancer are foregoing tamoxifen, the first FDA-approved drug for prevention of breast cancer, due to concerns about side effects, increased risk of other cancers, and lack of information, a new study by researchers in Boston shows. The study was published in the December 14 in the Journal of Clinical Oncology.
​Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have developed a method to synthesize modified forms of an established antibiotic called spectinomycin.
New classes of therapeutic antisense oligonucleotides can have toxic effects on the liver. A novel machine learning-based approach used to predict the hepatotoxic potential of an antisense drug based on its chemical sequence is presented in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.
Surprisingly, there are significantly more medical treatment episodes for upper extremity fractures than for those of lower extremity. The vast majority of forearm, hand and wrist fractures occur in pediatrics and young adults as they tend to be more active and involved in sporting activities.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Eprosartan Mesylate Tablets, 400 mg (base) and 600 mg (base).
› Verified 4 days ago
Christina Anne Chambers, M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 265 Lexington Blvd, Delaware, OH 43015 Phone: 614-323-3688 | |
Rhonda Granger, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 494 W Central Ave, Delaware, OH 43015 Phone: 740-369-3650 Fax: 740-369-0812 | |
Ondina Vega-behar, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2270 Warrensburg Rd, Delaware, OH 43015 Phone: 740-369-9614 | |
Emily A Lansden, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 494 W Central Ave, Delaware, OH 43015 Phone: 740-369-3650 Fax: 740-369-0812 | |
Alexandra Whaley, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 26 N Union St, Delaware, OH 43015 Phone: 740-362-9641 | |
Mrs. Tara Bergstedt, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 74 W William St, Delaware, OH 43015 Phone: 740-833-2384 |